Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
NGM Biopharmaceuticals, Inc
Rain Oncology Inc
Western Sydney Local Health District
Incyte Corporation
Incyte Corporation
Shenzhen BinDeBio Ltd.